Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Pharmacol Ther. 2016 Oct 19;170:166–180. doi: 10.1016/j.pharmthera.2016.10.018

Table 3.

Effect of GSTZ1 haplotype on DCA pharmacokinetics. Data are from volunteers who took DCA, 25 mg/kg/day, and patients with genetic mitochondrial diseases administered 12.5 mg/kg/12h, showing plasma clearance after the indicated dosing duration.

Plasma Clearance, ml/min Reference
GSTZ1C (EGT) carrier GSTZ1C (EGT) non-carrier
Volunteers, 1 dose 10.73 ± 6.88 (7) 7.08 ± 6.03 (5) Shroads et al. 2012
Volunteers, 5 days 2.22 ± 0.72 (7) 0.73 ± 0.84* (5) Shroads et al. 2012
Patients, 12 months 2.16 ± 0.99 (4) 0.91, 0.17 Shroads et al. 2012
Patients, 6 months 1.90 ± 1.13 (11) 0.53 ± 0.35* (6) Shroads et al. 2015
Patients, 30 months 2.08 ± 1.10 (11) 0.67 ± 0.45* (6) Shroads et al. 2015

Values shown are mean ± S.D. (n) or individual values where n<3.

*

Significantly different from EGT carriers, p<0.05